MedTrace Logo

Quantitative Liver Function Tests Using Cholates

NCT01907074 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2026-02-12

No results posted yet for this study

Summary

As the treatments for liver disease and the availability of liver transplantation have progressed, the number of patients with end stage liver disease continues to increase. This has increased the need to risk-stratify patients with cirrhosis to better direct their treatments and provide an accurate prognosis for their outcomes. The traditional assessment of the liver patient has been limited to imaging, static measures of "liver function tests" and liver biopsy. This protocol is designed to increase the spectrum of tests in the evaluation of the patient with end stage liver disease.

Conditions

  • End Stage Liver Disease

Interventions

DRUG

Cholates

Cholates is given intravenously (IV push) and by mouth, once per study visit

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • James Trotter, MD · Baylor Health Care System

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-23
Primary Completion
2020-05-19
Completion
2025-05-20

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01907074 on ClinicalTrials.gov